AJJ Medtech Holdings Limited, an investment holding company, provides integrated medical technology solutions for healthcare sector in Singapore. It develops, integrates, and sells complementary digital, artificial intelligence (AI), and robotics solutions. The company also offers Samsung Medison ultrasound medical devices and solutions for general imaging, women's health, and point-of-care applications; in-vitro diagnostics and life sciences, including point-of-care diagnostics equipment, such as blood glucose monitoring system and single-use rapid test kits, as well as laboratory diagnostics and life science products comprising portable diagnostics equipment, and reagents and consumables. In addition, it provides medical devices, including high-intensity focused ultrasound, general and plastic surgery devices, ward-side consumables, and CareX bed-side care robotics solutions; single-use disposables and advanced technology-driven equipment; and intra-oral scanners and dental burs. Further, the company offers management consultancy services for healthcare organizations; real estate leasing and management; nurseries and kindergarten services; hospital management, medical technology, biotechnology, and technology development; conducts research and development of medical technologies, manufactures and repairs irradiation and electromedical HIFU machines and other medical equipment; and wholesales medical, professional, scientific, and precision equipment. Additionally, it provides childcare wellness education materials; rents property; and healthcare digital products. The company was formerly known as OEL (Holdings) Limited and changed its name to AJJ Medtech Holdings Limited in February 2024. AJJ Medtech Holdings Limited was incorporated in 1984 and is based in Singapore.
Metrics to compare | AJJM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAJJMPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.2x | −12.1x | −0.5x | |
PEG Ratio | 0.96 | −0.10 | 0.00 | |
Price/Book | −1.8x | 7.7x | 2.6x | |
Price / LTM Sales | 1.7x | 1.8x | 3.3x | |
Upside (Analyst Target) | - | 42.8% | 43.3% | |
Fair Value Upside | Unlock | 5.2% | 6.9% | Unlock |